透過您的圖書館登入
IP:3.138.102.178
  • 學位論文

探討小分子C-2對Protein-X促進amyloid beta寡聚合及細胞毒性之研究

Investigation of a small molecule, C-2, for its anti- Protein-X inducing amyloid beta oligomerization and cytotoxicity

指導教授 : 林榮耀 賴韻如

摘要


阿茲海默氏症(Alzheimer’s disease, AD)已被視為常見的神經退化性疾病,主要病因為海馬迴的神經元受損,同時也引起認知功能障礙的出現。AD特徵包括由細胞內蛋白tau過度磷酸化所造成的神經纖維糾結(neurofibrillary tangles, NFTs)及細胞外類澱粉蛋白-β肽(β-amyloid peptide, Aβ)聚集形成的類澱粉斑塊(plaques)。目前,我們實驗室已發現,與年幼的小鼠相比,年老的AD模式鼠具有較高表現量的X蛋白。為了更進一步了解X蛋白在AD中的作用機制,我們藉由轉殖入X蛋白的SH-SY5Y細胞株作為本實驗使用的模式細胞。在細胞存活率方面以及西方墨點法的實驗中,從寡聚合物Aβ42中處理的細胞組別可以得知,經X蛋白的給予後會產生更多Aβ的聚集,使得細胞存活率降低,而處理小分子藥物的C-2能有效降低X蛋白所給予出的Aβ,進而達到拯救細胞的效果。因此,我們認為C-2可能透過抑制X蛋白而有效治療AD的小分子藥物。

並列摘要


Alzheimer’s disease (AD) has been considered as a common neurodegenerative disorder that causes hippocampal neurons damages and cognitive dysfunctions. AD features include neurofibrillary tangles (NFTs) caused by hyper-phosphorylation of intracellular tau protein, and extracellular β-amyloid (Aβ) plaques by Aβ aggregation. Our laboratory recently found that Protein-X level and the oligomerization of Aβ were concomitantly increased in aged triple transgenic AD mice (3xTg-AD) [PS1M146V, APPK670M/N671L, and tauP301L]. To further understand the mechanism of Protein-X in AD pathway, we established Protein-X stable-transfected SH-SY5Y cell line as the cell model in this experiment. In cell-based system and western blot analysis, Protein-X enhanced the formation of Aβ aggregation and the cytotoxicity is more than that in the present of Protein-X, implying that this cell-based system could serve as a platform for drug screening. Furthermore, we found that the small molecule, C-2, had the ability decrease the Aβ42 cytotoxicity induced by Protein-X. C-2 could be anticipated to develop a promising therapeutic agent for AD.

參考文獻


Ferri CP, Prince M, Brayne C, Brodaty H, Fratiglioni L, Ganguli M, Hall K, Hasegawa K, Hendrie H, Huang Y, Jorm A, Mathers C, Menezes PR, Rimmer E, Scazufca M. Alzheimer's Disease International. Global prevalence of dementia: a Delphi consensus study. Lancet. 2005; 366: 2112-7.
WHO (World Health Organization) http://www.who.int/en/
Thies W, Bleiler L. Alzheimer's disease facts and figures. Alzheimers Dement. 2013; 9: 208–45.
Luchsinger JA, Noble JM, Scarmeas N. Diet and Alzheimer’s disease. Curr Neurol Neurosci Rep. 2007; 7: 366-72.
Pohanka M. Cholinesterases, a target of pharmacology and toxicology. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub. 2011; 155: 219-29.

延伸閱讀